AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for RuvB-like 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y265

UPID:

RUVB1_HUMAN

Alternative names:

49 kDa TATA box-binding protein-interacting protein; 54 kDa erythrocyte cytosolic protein; INO80 complex subunit H; Nuclear matrix protein 238; Pontin 52; TIP49a; TIP60-associated protein 54-alpha

Alternative UPACC:

Q9Y265; B2R5S0; P82276; Q1KMR0; Q53HK5; Q53HL7; Q53Y27; Q9BSX9

Background:

RuvB-like 1, known by alternative names such as TIP49a and Pontin 52, is a multifunctional protein involved in DNA repair, transcriptional activation, and cell proliferation. It exhibits ATPase and DNA helicase activities, essential for its role in the NuA4 histone acetyltransferase complex, contributing to the acetylation of nucleosomal histones H4 and H2A. This modification facilitates transcriptional activation and DNA repair. Additionally, RuvB-like 1 is a core component of the INO80 complex, playing a crucial role in nucleosome remodeling.

Therapeutic significance:

Understanding the role of RuvB-like 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.